CohBar starts Phase la/lb trial of CB4211 for NASH and obesity
CohBar has commenced a Phase la/lb clinical trial to evaluate CB4211, a potential treatment for non-alcoholic steatohepatitis (NASH) and obesity.
CohBar has commenced a Phase la/lb clinical trial to evaluate CB4211, a potential treatment for non-alcoholic steatohepatitis (NASH) and obesity.